AB1045 Effect of strontium ranelate on vertebral pain syndrome and functional abilities in women with glucocorticoid induced osteoporosis

Aim To evaluate the effect of strontium ranelate in treatment of women with glucocorticoidinduced osteoporosis. Methods There were examined 241 women with glucocorticoidinduced osteoporosis (average age 59,6±11,1 years, average height 161,3±6,4 cm, average weight 70,4±12,8 kg). Evaluation of pain syndrome and level of physical activity was carried out with visual analogue scale (VAS). Examination was performed before onset of treatment and after a four, eight and twelve month treatment course. Strontium ranelate (Bivalos, “Servier”) was taken in a dose of one 2 g sachet as a suspension in water once a day and 1 tablet of Calcemin-advance (Calcium – 500 mg, Vit. D – 400 IU) 2 times a day during 12 months. Results The patients had the risk factors of osteoporosis: 24% of patients had osteoporotic fractures in their anamnesis; 19% – hip fractures in mother or father of patients and 28% – smoking. We observed a reliable decrease of vertebral pain syndrome after four months of treatment by 14%, after eight months – 35%; after twelve months – 47% (d